Pharma BD Deal Intelligence

Sanofi SA / Inhibrx Inc.

2024 · Acquisition/Merger · $2.2B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Sanofi acquired Inhibrx for up to $2.2B for AATD treatment.

Key facts

Announced Jan 23, 2024
Closed May 30, 2024
Deal value $2.2B
Deal type Acquisition/Merger
Therapeutic area Rare Disease
Indications Alpha-1 antitrypsin deficiency (AATD) emphysema
Key assets INBRX-101 (efdoralprin alfa / SAR447537)
Mechanism Recombinant human alpha-1 antitrypsin Fc-fusion protein (AAT augmentation; inhibits neutrophil elastase)